Tracking every rollback, reversal, and overreach — and the path back to the America we know.
The Trump administration announced 100% tariffs on patented drugs to force pharmaceutical companies into pricing negotiations and shift manufacturing to America. This action leverages tariff threats to compel drugmakers into 'most-favored nation' pricing deals. The policy directly impacts drug prices and availability for American consumers while pressuring companies to relocate production domestically.
Executive Order 14325 was signed on July 31, 2025, amending duties related to addressing the flow of illicit drugs across the U.S.-Canada border. The order modifies enforcement protocols and responsibilities for federal agencies involved in drug interdiction at the northern border. It directly impacts border security operations, law enforcement resources, and cross-border drug trafficking enforcement.
President Trump signed Executive Order 14297 to implement Most-Favored-Nation (MFN) pricing for prescription drugs, requiring Medicare to pay no more than the lowest price paid in other developed nations. The order aims to reduce drug costs for American patients and Medicare spending by allowing the government to negotiate lower pharmaceutical prices based on international benchmarks.
Executive Order 14232 was signed on March 6, 2025, to address the flow of illicit drugs across the southern border through amendments to existing duties and enforcement procedures. The order modifies enforcement mechanisms and regulatory approaches to combat drug trafficking at the U.S.-Mexico border. Direct impacts include increased border enforcement activities and potential changes to trade and customs operations affecting border communities and commerce.
Executive Order 14226 amends duties and enforcement procedures addressing drug trafficking across the U.S.-Canada border. The order modifies federal agencies' responsibilities in intercepting illicit drugs entering from the north. It directly impacts border enforcement operations, drug interdiction efforts, and cross-border trade procedures.
On February 1, 2025, President Trump signed Executive Order 14193 imposing duties on goods crossing the northern U.S. border, stated as a measure to address illicit drug flows. The order establishes tariffs on northern border trade. Direct impacts on Americans include potential increased costs for goods imported from Canada and potential changes to cross-border trade operations.
President Trump signed Executive Order 13948 on September 13, 2020, directing the Department of Health and Human Services to allow Medicare to pay no more for drugs than the lowest price paid in other developed countries. The order applied to a subset of Medicare Part B drugs. As of 2021, the rule was blocked by federal courts before implementation, preventing direct Medicare price changes for most drugs covered under the order.
On July 24, 2020, President Trump signed Executive Order 13937, directing the Department of Health and Human Services to establish a Most Favored Nation (MFN) model for Medicare drug pricing. The order required Medicare to pay no more for drugs than the lowest price paid in other developed nations. The rule was implemented in November 2020 but was blocked by federal courts before taking effect, and was subsequently rescinded by the Biden administration in 2021.
On July 24, 2020, President Trump signed Executive Order 13938 directing the Department of Health and Human Services to establish a program permitting the importation of FDA-approved drugs from Canada and other countries at lower prices. The order instructed HHS to create a Safe Importation Action Plan within 30 days. As of early 2021, HHS had not implemented a functional importation program, though the administration issued guidance on the policy direction.
On July 24, 2020, President Trump signed Executive Order 13947 directing federal agencies to take steps to lower drug prices and increase price transparency. The order instructed the Department of Health and Human Services to allow states to import prescription drugs from Canada, permit Medicare to negotiate drug prices directly, and require drug manufacturers to disclose prices in direct-to-consumer advertising. Implementation faced legal challenges and delays; some provisions did not take effect during the Trump administration.